Evidence-Based Management of Anticoagulant Therapy¶
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., et al. (2012). Evidence-Based Management of Anticoagulant Therapy. Chest.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Domain-specific¶
- Adverse Drug Event
- The drug has a narrow therapeutic window, so patients are dosed to a target INR (International Normalized Ratio), typically about 2–3
This sourceGives the management rule the sentence states: warfarin is a narrow-therapeutic-index drug, dosed to a target INR of 2.0 to 3.0 (Grade 1B) for vitamin K antagonist therapy generally; particular indications such as mechanical mitral valve prostheses carry higher targets.
- The drug has a narrow therapeutic window, so patients are dosed to a target INR (International Normalized Ratio), typically about 2–3
Verification¶
This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.
Registry ID ref:acb3ecebaf97 · see in the full table